

H1 2017 Net Profit up 5.73%

(€m)	H1 2017	H1 2016	Change
Revenue	72.03	63.53	+ 13.38 %
Operating Profit	16.60	15.61	+ 6.35 %
Net Profit	11.05	10.45	+ 5.73 %
Net profit attributable to equity holders of the Parent	10.55	10.01	+ 5.41 %
Basic Earnings per Share (in €)	0.70	0.67	+ 5.41 %

On 22 September 2017, PHARMAGEST INTERACTIVE's Board of Directors, chaired by Thierry CHAPUSOT, reviewed and adopted the financial statements for the six-month period ended 30 June 2017. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

➤ **Earnings growth at 30 June 2017**

PHARMAGEST Group's revenue was up 13.38% from last year's same period. Excellent performances by each of the four Divisions contributed to PHARMAGEST Group's overall development.

Operating profit rose 6.35% to €16.60 million.

Net Profit came to €11.05 million (+5.73%) and Net Profit attributable to the Parent grew 5.41% in relation to the same period in 2016.

At 30 June 2017, Basic Earnings per Share amounted to €0.70, up from €0.67 one year earlier.

➤ **Consolidated balance sheet highlights**

At 30 June 2017, PHARMAGEST Group's net cash position had increased to €69.63 million, compared to €61.71 million at 30 June 2016.

Equity attributable to the Parent at 30 June 2017 amounted to €101 million.

➤ **H1 2017 operating highlights**

- **The Solutions for Pharmacy Division - Europe** remained on a positive track (with revenue up 3.45%), confirming the business momentum fuelled by success of "new products" introduced at the end of 2016 and important contracts awarded to supply equipment to pharmacy networks in Belgium which will start to produce results in the 2017 second half;

- **The Solutions for health and social care facilities Division** was "boosted" by the acquisition of DICSIT INFORMATIQUE and its diversification into the fast-growing hospital at home and homecare support segment. This Division offers good visibility for growth in recurrent revenue up 28.6%;
- For the 2017 first half, **the e-Health Division** was bolstered by the positive impact of the recently integrated companies SAILENDRA (on 1 January) and CAREMEDS / MULTIMEDS (on 1 February). As a result, PHARMAGEST Group today has the most extensive range of medication adherence solutions in France and Europe and is completely aligned with the strategic healthcare priorities of tomorrow;
- **The Fintech Division** posted excellent performances in the 2017 first half. The development of its mobile application, deliberately streamlined to supplement the web platform, contributed to providing greater effectiveness and faster response times in communicating agreements.

➤ **H1 2017 outlook**

PHARMAGEST Group is confident that its targets will be met and confirms that its business development efforts remain on track.

In accordance with its strategic ambitions, PHARMAGEST Group is committed to being an even more active stakeholder in contributing to modernization of the healthcare systems in France and Europe. With this objective, it will continue to develop its "patient-centred" platform by proposing a dedicated global ecosystem.

In addition, with the recent acquisition of AXIGATE, PHARMAGEST Group is today the only player capable of addressing throughout Europe an offering for coordinated care across "non-hospital and hospital" pathways. Its ambitions for international development has thus been strengthened and PHARMAGEST Group is now very well-positioned to pursue discussions with other key European partners.

Financial calendar:

- Large and MidCap Event - Paris, 4 and 5 October 2017
- Publication of Q3 2017 sales: 17 November 2017

About PHARMAGEST Group:

Pharmagest Group is the French pharmacy information technology leader, with a market share of more than 41% and more than 900 employees. The Group's strategy is based on a core business of improving healthcare through information technology innovation and developing two priority areas: 1/ Services and technologies for healthcare professionals, with a focus on assisting pharmacies in patient medication compliance; and 2/ technologies for improving the efficacy of healthcare systems.

To roll out this strategy, Pharmagest Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for pharmaceutical laboratories, connected health devices and apps, and a sales financing marketplace.

These businesses are divided into four divisions: Solutions for Pharmacy Division – Europe; Solutions for Health and Social Care Facilities; Solutions for e-Health; and FinTech.

Listed on Euronext Paris™ - Compartment B
Indices: CAC® SMALL and CAC® All-Tradable par inclusion
Eligible for the Long-Only Deferred Settlement Service (SRD)
ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP



For all the latest news go to www.pharmagest.com

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Jean-Yves Samson
Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@pharmagest.com

Media Relations:

FIN'EXTENSO – Isabelle APRILE
Tel. +33 (0)1 39 97 61 22 – i.aprile@finextenso.fr